Last reviewed · How we verify
Qvar (100 mcg)
Qvar is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.
Qvar is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Asthma maintenance therapy in adults and children.
At a glance
| Generic name | Qvar (100 mcg) |
|---|---|
| Also known as | Beclomethasone diproprionate |
| Sponsor | Research in Real-Life Ltd |
| Drug class | Inhaled corticosteroid (ICS) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Beclomethasone dipropionate (the active ingredient in Qvar) is a corticosteroid that suppresses inflammatory responses in the airways by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced recruitment of immune cells. This results in decreased airway inflammation, mucus production, and bronchial hyperresponsiveness in asthma patients.
Approved indications
- Asthma maintenance therapy in adults and children
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Oral candidiasis
- Hoarseness
Key clinical trials
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure (PHASE4)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161) (PHASE3)
- TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD (PHASE4)
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Qvar (100 mcg) CI brief — competitive landscape report
- Qvar (100 mcg) updates RSS · CI watch RSS
- Research in Real-Life Ltd portfolio CI